17 research outputs found
Rationale and design of the Early valve replacement in severe ASYmptomatic Aortic Stenosis Trial
Background: Aortic valve replacement in asymptomatic severe aortic stenosis is controversial. The Early valve replacement in severe ASYmptomatic Aortic Stenosis (EASY-AS) trial aims to determine whether early aortic valve replacement improves clinical outcomes, quality of life and cost-effectiveness compared to a guideline recommended strategy of ‘watchful waiting’. Methods: In a pragmatic international, open parallel group randomized controlled trial (NCT04204915), 2844 patients with severe aortic stenosis will be randomized 1:1 to either a strategy of early (surgical or transcatheter) aortic valve replacement or aortic valve replacement only if symptoms or impaired left ventricular function develop, or other cardiac surgery becomes nessessary. Exclusion criteria include other severe valvular disease, planned cardiac surgery, ejection fraction <50%, previous aortic valve replacement or life expectancy <2 years. The primary outcome is a composite of cardiovascular mortality or heart failure hospitalization. The primary analysis will be undertaken when 663 primary events have accrued, providing 90% power to detect a reduction in the primary endpoint from 27.7% to 21.6% (hazard ratio 0.75). Secondary endpoints include disability-free survival, days alive and out of hospital, major adverse cardiovascular events and quality of life. Results: Recruitment commenced in March 2020 and is open in the UK, Australia, New Zealand, and Serbia. Feasibility requirements were met in July 2022, and the main phase opened in October 2022, with additional international centers in set-up. Conclusions: The EASY-AS trial will establish whether a strategy of early aortic valve replacement in asymptomatic patients with severe aortic stenosis reduces cardiovascular mortality or heart failure hospitalization and improves other important outcomes.</p
The NightLife study — the clinical and cost-effectiveness of thrice-weekly, extended, in-centre nocturnal haemodialysis versus daytime haemodialysis using a mixed methods approach: study protocol for a randomised controlled trial
Background:
In-centre nocturnal haemodialysis (INHD) offers extended-hours haemodialysis, 6 to 8 h thrice-weekly overnight, with the support of dialysis specialist nurses. There is increasing observational data demonstrating potential benefits of INHD on health-related quality of life (HRQoL). There is a lack of randomised controlled trial (RCT) data to confirm these benefits and assess safety.
Methods:
The NightLife study is a pragmatic, two-arm, multicentre RCT comparing the impact of 6 months INHD to conventional haemodialysis (thrice-weekly daytime in-centre haemodialysis, 3.5–5 h per session). The primary outcome is the total score from the Kidney Disease Quality of Life tool at 6 months. Secondary outcomes include sleep and cognitive function, measures of safety, adherence to dialysis and impact on clinical parameters. There is an embedded Process Evaluation to assess implementation, health economic modelling and a QuinteT Recruitment Intervention to understand factors that influence recruitment and retention. Adults (≥ 18 years old) who have been established on haemodialysis for > 3 months are eligible to participate.
Discussion:
There are 68,000 adults in the UK that need kidney replacement therapy (KRT), with in-centre haemodialysis the treatment modality for over a third of cases. HRQoL is an independent predictor of hospitalisation and mortality in individuals on maintenance dialysis. Haemodialysis is associated with poor HRQoL in comparison to the general population. INHD has the potential to improve HRQoL. Vigorous RCT evidence of effectiveness is lacking. The NightLife study is an essential step in the understanding of dialysis therapies and will guide patient-centred decisions regarding KRT in the future.
Trial registration:
Trial registration number: ISRCTN87042063. Registered: 14/07/2020
Pathway-based subnetworks enable cross-disease biomarker discovery.
Biomarkers lie at the heart of precision medicine. Surprisingly, while rapid genomic profiling is becoming ubiquitous, the development of biomarkers usually involves the application of bespoke techniques that cannot be directly applied to other datasets. There is an urgent need for a systematic methodology to create biologically-interpretable molecular models that robustly predict key phenotypes. Here we present SIMMS (Subnetwork Integration for Multi-Modal Signatures): an algorithm that fragments pathways into functional modules and uses these to predict phenotypes. We apply SIMMS to multiple data types across five diseases, and in each it reproducibly identifies known and novel subtypes, and makes superior predictions to the best bespoke approaches. To demonstrate its ability on a new dataset, we profile 33 genes/nodes of the PI3K pathway in 1734 FFPE breast tumors and create a four-subnetwork prediction model. This model out-performs a clinically-validated molecular test in an independent cohort of 1742 patients. SIMMS is generic and enables systematic data integration for robust biomarker discovery
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
This analysis, of 2483 patients with acute myeloid leukaemia (AML) aged
60+ years entered into two UK trials, was performed to determine the
baseline parameters related to survival and to develop a risk index. The
Medical Research Council (MRC) AML11 trial (n = 1071) was used to
develop the index; this was validated using data from the Leukaemia Research
fund (LRF) AML14 trial on 1137 intensively (AML14I) and 275 nonintensively
(AML14NI) treated patients. In AML11, cytogenetic group, age,
white blood count, performance status and type of AML (de novo, secondary)
were all highly significantly related to prognosis in multivariate analysis. The
regression coefficients were used to define good, standard and poor risk
groups, with 1-year survival of 53%, 43% and 16% respectively (P < 0Æ0001).
The risk index showed very good discrimination in both AML14I and
AML14NI (both P < 0Æ0001), thereby providing validation, although survival
in all groups was very poor in AML14NI. The risk factors for survival in older
AML patients were similar to those in younger ones and discrimination of
patient groups with relatively good to very poor prognosis was possible.
These risk groups apply to both intensively and non-intensively treated
patients. Randomized trials of intensive versus non-intensive therapy are
needed to determine which types of patient should be given which type of
treatment
Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study
Purpose
Deregulation of key PI3K/AKT pathway genes may contribute to endocrine
resistance in breast cancer (BC). PIK3CA is the most frequently mutated
gene in luminal BC (similar to 35%); however, the effect of mutations
in helical versus kinase domains remains controversial. We hypothesize
that improved outcomes occur in patients with estrogen receptor-positive
(ER positive) BC receiving endocrine therapy and possessing PIK3CA
mutations.
Materials and Methods
DNA was extracted from 4,540 formalin-fixed paraffin-embedded BC samples
from the Exemestane Versus Tamoxifen-Exemestane pathology study.
Mutational analyses were performed for 25 mutations (PIK3CAx10, AKT1x1,
KRASx5, HRASx3, NRASx2 and BRAFx4).
Results
PIK3CA mutations were frequent (39.8%), whereas RAS/RAF mutations were
rare (<1%). In univariable analyses PIK3CA mutations were associated
with significantly improved 5-year distant relapse-free survival (DRFS;
HR, 0.76; 95% CI, 0.63 to 0.91; P = .003). However, a multivariable
analysis correcting for known clinical and biologic prognostic factors
failed to demonstrate that PIK3CA mutation status is an independent
prognostic marker for DRFS (HR, 0.92; 95% CI, 0.75 to 1.12; P = .4012).
PIK3CA mutations were more frequent in low-risk luminal BCs (eg, grade 1
node v 3, node-negative v-positive), confounding the relationship
between mutations and outcome.
Conclusion
PIK3CA mutations are present in approximately 40% of luminal BCs but
are not an independent predictor of outcome in the context of endocrine
therapy, whereas RAS/RAF mutations are rare in luminal BC. A complex
relationship between low-risk cancers and PIK3CA mutations was
identified. Although the PI3K/AKT pathway remains a viable therapeutic
target as the result of a high mutation frequency, PIK3CA mutations do
not seem to affect residual risk following treatment with endocrine
therapy. (C) 2014 by American Society of Clinical Oncolog
Recommended from our members
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine.
Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone. However, additional systemic chemotherapy treatment is necessary for others. The clinical challenges in managing high-risk women are to identify existing and novel druggable targets, and to identify those who would benefit from these therapies. Therefore, we performed mRNA abundance analysis using the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial pathology cohort to identify a signature of residual risk following endocrine therapy and pathways that are potentially druggable. A panel of genes compiled from academic and commercial multiparametric tests as well as genes of importance to breast cancer pathogenesis was used to profile 3825 patients. A signature of 95 genes, including nodal status, was validated to stratify endocrine-treated patients into high-risk and low-risk groups based on distant relapse-free survival (DRFS; Hazard Ratio = 5.05, 95% CI 3.53-7.22, p = 7.51 × 10-19). This risk signature was also found to perform better than current multiparametric tests. When the 95-gene prognostic signature was applied to all patients in the validation cohort, including patients who received adjuvant chemotherapy, the signature remained prognostic (HR = 4.76, 95% CI 3.61-6.28, p = 2.53× 10-28). Functional gene interaction analyses identified six significant modules representing pathways involved in cell cycle control, mitosis and receptor tyrosine signaling; containing a number of genes with existing targeted therapies for use in breast or other malignancies. Thus the identification of high-risk patients using this prognostic signature has the potential to also prioritize patients for treatment with these targeted therapies
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone. However, additional systemic chemotherapy treatment is necessary for others. The clinical challenges in managing high-risk women are to identify existing and novel druggable targets, and to identify those who would benefit from these therapies. Therefore, we performed mRNA abundance analysis using the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial pathology cohort to identify a signature of residual risk following endocrine therapy and pathways that are potentially druggable. A panel of genes compiled from academic and commercial multiparametric tests as well as genes of importance to breast cancer pathogenesis was used to profile 3825 patients. A signature of 95 genes, including nodal status, was validated to stratify endocrine-treated patients into high-risk and low-risk groups based on distant relapse-free survival (DRFS; Hazard Ratio = 5.05, 95% CI 3.53-7.22, p = 7.51 × 10-19). This risk signature was also found to perform better than current multiparametric tests. When the 95-gene prognostic signature was applied to all patients in the validation cohort, including patients who received adjuvant chemotherapy, the signature remained prognostic (HR = 4.76, 95% CI 3.61-6.28, p = 2.53× 10-28). Functional gene interaction analyses identified six significant modules representing pathways involved in cell cycle control, mitosis and receptor tyrosine signaling; containing a number of genes with existing targeted therapies for use in breast or other malignancies. Thus the identification of high-risk patients using this prognostic signature has the potential to also prioritize patients for treatment with these targeted therapies